Skip to main content

Mylan CEO Tries to Shift Focus

Amid numerous calls for state and federal investigations over pricing of its EpiPen, the drug company Mylan struck back, saying that 55 percent of the price goes to “middleman’’ insurers.

by Sarah Schroeder

Lead image for this article

Amid numerous calls for state and federal investigations over pricing of its EpiPen, the drug company Mylan struck back, saying that 55 percent of the price goes to “middleman’’ insurers. (Becker’s Hospital Review)

Information about the authors

Sarah Schroeder’s staff photo

Quality journalism doesn't come free

Perhaps it goes without saying — but producing quality journalism isn't cheap. At a time when newsroom resources and revenue across the country are declining, The Texas Tribune remains committed to sustaining our mission: creating a more engaged and informed Texas with every story we cover, every event we convene and every newsletter we send. As a nonprofit newsroom, we rely on members to help keep our stories free and our events open to the public. Do you value our journalism? Show us with your support.

Yes, I'll donate today